(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 February 2020 (20.02.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/036862 A9

(51) International Patent Classification:
C12N 15/113 (2010.01) *A61P 31/20* (2006.01)
A61K 31/713 (2006.01)

(21) International Application Number:
PCT/US2019/046142

(22) International Filing Date:
12 August 2019 (12.08.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/718,314 13 August 2018 (13.08.2018) US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.** [US/US]; 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **JADHAV, Vasant R.**; 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **MAIER, Martin A.**; 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **MILSTEIN, Stuart**; 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142 (US). **SCHLEGEL, Mark K.**; 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142 (US).

(74) Agent: **SARGEANT, Brooke** et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: The present disclosure relates to double stranded RNA agents targeting the hepatitis B virus (HBV) genome, and methods of using such agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection or HBV-associated disorder, *e.g.*, chronic hepatitis B infection.




FIG. 2A




FIG. 2B

WO 2020/036862 A9

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:
11 March 2021 (11.03.2021)

(15) Information about Correction:
see Notice of 11 March 2021 (11.03.2021)